Description
It’s Hard to Treat What You Can’t See:
The Molecular Diagnostics
Perspective in Oncology
Why should you register now for this webinar?
- In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic cancers. Many of these cytological specimens require molecular profiling to help confirm diagnoses and guide treatment decisions. Hear why a high Quantity Not Sufficient (QNS) from reference labs is unacceptable for your patients, especially after weeks of waiting, and how you can bring a robust amplicon-based comprehensive genomic profiling (CGP) in-house to ensure that you get answers when it counts.
- Brought to you by: CAP TODAY
- Moderated by: Bob McGonnagle, Publisher, CAP TODAY
- Presenter: Yi Ding, MD
What will this webinar empower you to do?
- Learn how to evaluate NGS technologies when considering bringing CGP in-house
- Engage with an experienced user of an amplicon-based CGP assay evaluating 517 genes and genomic signatures like homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI)
- Ask questions of our distinguished presenter
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific.